Oakville, Ontario–(Newsfile Corp. – June 17, 2024) – Psirenity Health announced today that it has signed a formal partnership with Bonita Medical Aesthetics & Wellness. Jessica Caceres, Nurse Practitioner and proprietor of Bonita, will become the Director of Women’s Health at Psirenity Health.
“Through this partnership, we will collaborate to expand our women’s health services and provide comprehensive care, including Hormone Therapy Review,” said Bryan G. Jones CEO of Psirenity Health.
Together, Psirenity Health and Bonita will leverage their collective expertise to offer innovative solutions tailored to the unique needs of women at every stage of life.
“We are all excited about the opportunity to expand our women’s health offering. Together, we can provide comprehensive care that addresses not only the physical but also the emotional and aesthetic needs of our members,” said Jessica Caceres, Owner of Bonita.
For more information about Psirenity Health and our Women’s Health services, please visit www.psirenity.com.
About Psirenity Health
Psirenity Health is a proactive, leading-edge health and wellness company that helps its members Live Better, Longer. It provides its members with physician curated nutraceuticals and hormone therapy review as well as fitness, nutritional and lifestyle guidance. Members are provided with virtual tools to be their best today and maintain their wellbeing for tomorrow with optimized energy, mood, sleep, brain health, heart health, appearance and more.
For more information, please contact bryan@psirenity.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213296
The DEA was created to combat cartel trafficking, protect public health, and ensure researchers have…
CAMBRIDGE, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology…
Longer-term analyses reinforce duvelisib’s activity across treatment-experienced PTCL populations, including patients with ≥3 prior lines…
- Combination of evorpacept plus rituximab and lenalidomide (R2) generated complete responses (CR) in 92%…
Media ReleaseCOPENHAGEN, Denmark; December 7, 2025 Trial demonstrated treatment with fixed duration EPKINLY plus rituximab…
― Clear dose-response observed, with a robust and clinically meaningful fetal hemoglobin (HbF) induction at…